Left Menu
Development News Edition

UPDATE 3-U.S and European regulators reviewing safety of heartburn drugs like Zantac

Reuters | Washington DC | Updated: 14-09-2019 02:10 IST | Created: 14-09-2019 02:09 IST
UPDATE 3-U.S and European regulators reviewing safety of heartburn drugs like Zantac
Image Credit: Pixnio

U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac, after they found traces of a probable cancer-causing impurity in some versions of the medicine. The U.S. Food and Drug Administration said it had found traces of the impurity, called N-nitrosodimethylamine (NDMA), in some of drugs with ranitidine in them. Both the FDA and the European Medicines Agency said they will review the drug's safety, but neither agency is currently calling for patients to stop taking it.

The impurity in ranitidine was first flagged to the regulators by Valisure, an online pharmacy that tests the medication it sells for flaws. Valisure said in its report that it found the impurity in both Sanofi SA's branded Zantac as well as generic versions of the drug. But the FDA would not confirm in which versions of the drug it had found the impurity, noting that it found quite different - and lower - amounts of NDMA in the drugs.

David Light, Valisure's chief executive officer, said his company believes that because ranitidine is unstable, the impurity can form on its own, rather than being introduced by problems in the manufacturing process. He said its possible that the impurity has been in the drug for as long as it has been on the market. "It seems to be that there's an inherent problem with the drug itself," Light said in an interview. "There's a lot of concerns that, in our mind, justify completely recalling this product."

The FDA said it has not determined how long the impurity has been present in Zantac. Sanofi, whose stock price was little changed, said in a statement that it takes safety seriously and is committed to working with the FDA. It said Zantac meets all specified safety requirements for use in the over-the-counter market.

NDMA is one of the impurities that has been found in blood pressure and heart failure medicines called Angiotensin II Receptor Blockers (ARBs). Those impurities are believed to have been introduced by recent changes in the manufacturing processes for ARBs. Regulators have been recalling those drugs since last year, and the FDA expanded its investigation of the impurities beyond that class of drugs last month.

Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in an interview that regulators around the world were considering requiring new testing during the manufacturing process to reduce contamination of drugs. "We're going to have to be more vigilant," Woodcock said. "I think you'll see tests added at the appropriate point during the manufacturing."

Blood pressure and heart failure medicines such as valsartan, the generic version of Novartis AG's Diovan, have been recalled by drugmakers such as Mylan NV, Teva Pharmaceutical Industries and Novartis' Sandoz, as the drugs have been found to contain probable carcinogens.

Also Read: UPDATE 2-U.S and European regulators reviewing safety of heartburn drugs like Zantac


TRENDING

OPINION / BLOG / INTERVIEW

Post-COVID-19 Nigeria needs a robust Health Management Information System to handle high disease burden

Nigeria is among a few countries that conceptualised a health management information system HMIS in the early 90s but implementation has been a challenge till date. Besides COVID-19, the country has a huge burden of communicable and non-com...

Morocco COVID-19 response: A fragile health system and the deteriorating situation

Learning from its European neighbors, Morocco imposed drastic measures from the initial stages of the COVID-19 outbreak to try to contain its spread. The strategy worked for a few months but the cases have surged after mid-June. In this sit...

COVID-19: Argentina’s health system inefficiencies exaggerate flaws of health information system

You can recover from a drop in the GDP, but you cant recover from death, was the straightforward mindset of Argentinas President Alberto Fernndez and defined the countrys response to COVID-19. The South American nation imposed a strict...

Rwanda’s COVID-19 response commendable but health information system needs improvement

Rwanda is consistently working to improve its health information system from many years. However, it is primarily dependent on the collection and reporting of health data on a monthly basis. Besides, evaluation studies on Rwandas HIS publis...

Videos

Latest News

Venezuela's Maduro calls on U.N. members to rally against U.S. sanctions

Venezuelan President Nicolas Maduro told the U.N. General Assembly on Wednesday all countries that defend peace should rally against U.S. sanctions clamped on the South American country and its allies like Cuba, Nicaragua and Syria. The Tru...

Trump lauds move by Kentucky governor to call up National Guard

U.S. President Donald Trump welcomed a decision by Kentuckys governor to call in the National Guard after prosecutors cleared police officers of criminal charges in the death of Breonna Taylor, a Black medical worker killed in March. Trump ...

COVID-19 smartphone app finally launches in England and Wales

England and Wales launch a COVID-19 smartphone app on Thursday, allowing users to trace contacts, check the local level of risk and record visits to venues such as pubs, four months after the technology was promised to the public. The NHS C...

Proposed Nicaragua law could muffle dissent

Nicaraguas governing party is pushing a bill that would require people, businesses and non-governmental groups that receive money from outside the country to register as foreign agents, saying it is an attempt to prevent foreign interferenc...

Give Feedback